JTC-801

• Catalog No.: S2722
• CAS Number: 244218-51-7
• M. F.: C26H26ClN3O2
• M. W.: 447.95654
• Storage: -20°C

SYNONYMS

• IUPAC name: N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide hydrochloride
• IUPAC Traditional name: N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide hydrochloride

DATABASE IDS

• CAS Number: 244218-51-7

PROPERTIES

• Target: Opioid receptor
• Salt Data: HCL
• Storage Condition: -20°C

DETAILS

Description (English)

Biological Activity

• Description: JTC-801 is a selective opioid receptor-like1 (ORL1) receptor antagonist with IC50 of 94 nM.
• Targets:

  Opioid receptor-like1 (ORL1)

• IC50:

  94 nM ^[1]

• In Vitro: JTC-801 displays about 12.5-, 129-, and 1055-fold selectivity for ORL1 receptor (K_i = 8.2 nM) over μ-, κ-, and δ-opioid receptors, respectively. JTC-801 does not inhibit forskolin-stimulated cyclic AMP accumulation in human ORL1 receptor-expressing HeLa cells, but it prevents nociceptin-induced inhibition of cyclic AMP accumulation, indicating that JTC-801 possesses full antagonistic activity. ^[2] In rat cerebrocortical membrane, JTC-801 inhibits ORL1 receptor with IC50 of 472 nM and μ-receptor with IC50 of 1831 nM. JTC-801 completely antagonizes the suppression of nociceptin on forskolin-induced accumulation of cyclic AMP with IC50 of 2.58 μM in HeLa cells expressing ORL1 receptor. ^[1]
• In Vivo: Oral administration of JTC-801 (0.3-3 mg/kg) antagonizes nociceptin-induced allodynia in mice, and shows analgesic effect in a hot plate test using mice and in a formalin test using rats. ^[2] In mouse hot-plate test, JTC-801 prolongs escape response latency (ERL) or exposed heat stimulus with minimum effective doses (MED) of 0.01 mg/kg by i.v. or 1 mg/kg by p.o. In the rat formalin test, JTC-801 reduces both the first and second phases of the nociceptive response with MED of 0.01 mg/kg71 by i.v. or 1 mg/kg by p.o. ^[1] JTC-801 dose-dependently normalizes paw withdrawal latency (PWL). Although JTC-801 does not inhibit a chronic constriction injury (CCI)-induced decrease in bone mineral content (BMC) and bone mineral density (BMD), it inhibits an increase in the number of osteoclasts. ^[3] Tactile allodynia induced by L5/L6 spinal nerve ligation is reversed by both systemic (3-30 mg/kg) and spinal (22.5 and 45 pg) JTC-801 in a dose-dependent manner. Furthermore, systemic JTC-801 reduces Fos-like immunoreactivity in the dorsal horn of the spinal cord (laminae I/II). ^[4] JTC-801 produces dose-dependent mechanical and cold anti-allodynic effects with ED50 of 0.83 mg/kg and 1.02 mg/kg, respectively. ^[6]

Combination Therapy

• Description:

  JTC-801 (1 mg/kg, i.p.) blocks a significant proportion of the hypothermia caused by WIN 55212-2 (2.5, 5, and 10 mg/kg, i.p.) or another cannabinoid agonist, CP-55940 (1 mg/kg, i.p.). ^[5] JTC-801 in combination with WIN 55212-2 produces greater anti-allodynic effects, compared with the dose-response curves of each drug alone. ^[6]

Protocol

• Protocol: Kinase Assay ^[1]
• Human ORL1 receptor binding affinity: Human ORL1 receptor expressed in HeLa cells are harvested and homogenized in 50 mM Tris buffer (pH 7.4) containing 1 mM EDTA. After centrifugation for 30 minutes at 40,000×g, the pellets are resuspended in buffer containing 50 mM Tris, supplemented with 10 mM MgCl₂ and 2 mM EGTA, and used as membrane preparations. 50 mM Tris (pH 7.4) supplemented with 2 mM EDTA and 0.1 mM (p-amidoinophenyl) methanesulphonyl fluoride hydrochloride containing 0.2% bovine serum albumin is used for the binding buffer. For saturation binding assay, the cell membrane preparations are incubated for 60 minutes at 24 °C with various concentrations of [^3H]-nociceptin. Nonspecific binding is determined in the presence of 1 mM unlabelled nociceptin. For competitive assay, the cell membrane preparations (4.17 μg/well) are incubated for 60 minutes at 24 °C with 50 pM [^3H]-nociceptin in the presence of various concentrations of JTC-801 (10 nM-10 μM). JTC-801 is dissolved in DMSO and diluted in binding buffer, and then added to the incubation mixture. Final concentration of vehicle is 1% DMSO in binding buffer. After incubation for 60 minutes, the membrane preparations are rapidly filtrated over Whatman GF/B glass filters which are pretreated with 0.1% polyethyleneimine, and the radioactivity on each filter is measured by liquid scintillation counting. IC50 value is calculated as the concentration of JTC-801 required to displace 50% inhibition of the [^3H]-nociceptin.
• Protocol: Animal Study ^[1]
• Animal Models: Male ICR (CD-1) subjected to nociceptin-induced allodynia test or hot plate test, and Male SD rats subjected to formalin-induced paw-licking response
• Formulation: Suspended in 0.5% methyl cellulose solution or dissolved in 5% sorbitol
• Doses: ~10 mg/kg
• Administration: Orally or injected i.v.

References

• References: [1] Yamada H, et al. Br J Pharmacol, 2002, 135(2), 323-332.
• References: [2] Shinkai H, et al. J Med Chem, 2000, 43(24), 4667-4677.
• References: [3] Suyama H, et al. Neurosci Lett, 2003, 351(3), 133-136.
• References: [4] Tamai H, et al. Eur J Pharmacol, 2005, 510(3), 223-228.
• References: [5] Rawls SM, et al. Neuropeptides, 2007, 41(4), 239-247.
• References: [6] Gunduz O, et al. Pharmacol Biochem Behav, 2011, 99(4), 540-544.

REFERENCES

• Yamada H, et al. Br J Pharmacol, 2002, 135(2), 323-332.
• Shinkai H, et al. J Med Chem, 2000, 43(24), 4667-4677.
• Suyama H, et al. Neurosci Lett, 2003, 351(3), 133-136.
• Tamai H, et al. Eur J Pharmacol, 2005, 510(3), 223-228.
• Rawls SM, et al. Neuropeptides, 2007, 41(4), 239-247.
• Gunduz O, et al. Pharmacol Biochem Behav, 2011, 99(4), 540-544.